O
NBSE

OrbiMed’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

OrbiMed’s Portfolio NBSE Stock Details NBSE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-18,556
Closed -$2.64M – 161
2020
Q1 		$2.64M Buy
+18,556
New +$2.46M 0.04% 122

Other funds holding NBSE

GC
Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OrbiMed's NBSE Position: Q2 2020 in Review

OrbiMed sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q2 2020, closing a stake of 18,556 shares — an estimated $2.64M sold.

OrbiMed first reported a position in NBSE in Q1 2020 and held it in 1 quarter. The position peaked at $2.64M in Q1 2020. 49 funds tracked by Wall St. Rank hold NBSE as of Q2 2020.

  • OrbiMed reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
  • OrbiMed sold 18,556 NeuBase Therapeutics, Inc. Common Stock shares in Q2 2020, an estimated $2.64M.
  • OrbiMed first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q1 2020 and held it in 1 quarter.
  • OrbiMed's NeuBase Therapeutics, Inc. Common Stock position peaked at $2.64M in Q1 2020.
  • 49 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q2 2020.

Based on OrbiMed's 13F filing for Q2 2020, filed 14 Aug 2020.